Allogeneic expanded adipose-derived mesenchymal stem cell therapy for perianal fistulas in Crohn's disease: A case series.
Crohn's disease
fistula closure
inflammatory bowel disease
mesenchymal stem cell therapy
perianal complex fistula
Journal
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
ISSN: 1463-1318
Titre abrégé: Colorectal Dis
Pays: England
ID NLM: 100883611
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
12
01
2021
received:
30
09
2020
accepted:
08
02
2021
pubmed:
18
2
2021
medline:
4
9
2021
entrez:
17
2
2021
Statut:
ppublish
Résumé
Even with optimal medical and surgical therapy, perianal fistulas in patients with Crohn's disease (CD) have low closure rates. As a new therapeutic option, administration of local mesenchymal stem cells (MSCs) has proved to be an innovative option after failure of treatment with immunosuppressive or immunomodulatory agents. The aim of this work is to share our first experience with MSC administration and demonstrate its efficacy, safety and feasibility outside a clinical trial. A total of 11 CD patients with complex perianal fistulas with nonactive or mildly active luminal disease were treated with local injection of 120 million allogeneic adipose-derived stem cells at a tertiary hospital between February 2019 and June 2020. The mean age of the 11 patients was 38.3 years, 72.7% were men and 27.2% were smokers. The mean duration of fistula manifestation was 7.8 years and, except for one patient (therapy with tacrolimus), all other patients had been treated with an antitumour necrosis factor agent without fistula healing in the last 6 months. After a mean follow-up time of 41.5 weeks, 72.7% (8/11) of patients had complete closure of their fistula and three patients failed MSC treatment. Complete fistula healing could be observed 4-6 weeks postoperatively in half of the patients, while 36.5% (4/11) of patients developed a perianal abscess which had to be drained. One patient experienced cytomegalovirus viraemia 2 weeks after MSC administration and one patient developed a testicular carcinoma 16 weeks after treatment. This case series demonstrates that the efficacy and safety of darvadstrocel in the ADMIRE trial can be replicated outside a clinical trial. This new modality in the treatment of complex perianal fistulas appears to be a promising therapeutic option for a challenging patient population.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1444-1450Informations de copyright
© 2021 The Association of Coloproctology of Great Britain and Ireland.
Références
Kasparek MS, Glatzle J, Temeltcheva T, Mueller MH, Koenigsrainer A, Kreis ME. Long-term quality of life in patients with Crohn's disease and perianal fistulas: influence of fecal diversion. Dis Colon Rectum. 2007;50:2067-74.
Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology. 2006;130:650-6.
Schwartz DA, Loftus EV Jr, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875-80.
Schwartz DA, Tagarro I, Carmen Diez M, Sandborn WJ. Prevalence of fistulizing Crohn's disease in the United States: estimate from a systematic literature review attempt and population-based database analysis. Inflamm Bowel Dis. 2019;25(11):1773-9.
Dewint P, Hansen BE, Verhey E, Oldenburg B, Hommes DW, Pierik M, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014;63:292-9.
Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-85.
Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand R, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-405.
Yarur AJ, Kanagala V, Stein DJ, Czul F, Quintero MA, Agrawal D, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease. Aliment Pharmacol Ther. 2017;45:933-40.
Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis. 2003;9:98-103.
Hong MK, Craig Lynch A, Bell S, Woods RJ, Keck JO, Johnston MJ, et al. Faecal diversion in the management of perianal Crohn's disease. Colorectal Dis. 2011;13:171-6.
Valencia J, Blanco B, Yanez R, Vázquez M, Herrero Sánchez C, Fernández-García M, et al. Comparative analysis of the immunomodulatory capacities of human bone marrow- and adipose tissue-derived mesenchymal stromal cells from the same donor. Cytotherapy. 2016;18:1297-311.
Garcia-Olmo D, Herreros D, Pascual I, Pascual JA, Del-Valle E, Zorrilla J. Expanded adipose-derived stem cells for the treatment of complex perianal fistula. Dis Colon Rectum. 2009;52:79-86.
Panés J, García-Olmo D, Van Assche G,Colombel JF, Reinisch W, Baumgart DC, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388:1281-90.
Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, et al. Long-term efficacy and safety of stem cell therapy (cx601) for complex perianal fistulas in patients with Crohn's disease. Gastroenterology. 2018;154:1334-42.e4.
Spinelli AG-OD, Garcia-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart D, et al. Stem cell therapy (darvadstrocel) for treatment-refractory complex perianal fistulas in patients with Crohn’s disease: 2-year efficacy and safety data. Poster Presentation European Colorectal Congress. 2019.
Ciccocioppo R, Klersy C, Leffler DA, Rogers R, Bennett D, Corazza GR, et al. Systematic review with meta-analysis: safety and efficacy of local injections of mesenchymal stem cells in perianal fistulas. JGH Open. 2019;3:249-60.
Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, et al. Safety of cell therapy with mesenchymal stromal cells (safecell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012;7:e47559.
Nolan N, Halai UA, Regunath H, Smith L, Rojas-Moreno C, Salzer W. Primary cytomegalovirus infection in immunocompetent adults in the United States - a case series. IDCases. 2017;10:123-6.
Pillet S, Jarlot C, Courault M, Del Tedesco E, Chardon R, Saint-Sardos P, et al. Infliximab does not worsen outcomes during flare-ups associated with cytomegalovirus infection in patients with ulcerative colitis. Inflamm Bowel Dis. 2015;21:1580-6.
Rowan C, Judge C, Cannon MD, Cullen G, Mulcahy HE, Ryan E et al. Severe symptomatic primary cmv infection in inflammatory bowel disease patients with low population seroprevalence. Gastroenterol Res Pract. 2018;2018:1029401.
Subramanian V, Finlayson C, Harrison T, Rice P, Pollok R. Primary cytomegalovirus infectious colitis complicating Crohn's disease successfully treated with oral valganciclovir. J Crohns Colitis. 2010;4:199-202.
Lin W, Huang L, Li Y, Fang B, Li G, Chen L, et al. Mesenchymal stem cells and cancer: clinical challenges and opportunities. Biomed Res Int. 2019;2019:2820853.
Chulpanova DS, Kitaeva KV, Tazetdinova LG, James V, Rizvanov AA, Solovyeva VV. Application of mesenchymal stem cells for therapeutic agent delivery in anti-tumor treatment. Front Pharmacol. 2018;9:259.
Barnhoorn MC, Van Halteren AGS, Van Pel M, Molendijk I, Struijk AC, Jansen PM, et al. Lymphoproliferative disease in the rectum 4 years after local mesenchymal stromal cell therapy for refractory perianal Crohn's fistulas: a case report. J Crohns Colitis. 2019;13:807-11.